SmartGene
한국어/English
STAR PipelineCat

STAR-M3W

Feline obesity · Felinized GLP-1 receptor agonist

Our Pipelines

Overview

Species
Cat
Indication
Feline obesity
Target
GLP-1 receptor
Modality
Felinized GLP-1 receptor agonist
Current Stage
Cell Line
Route
Own approval
Own Approval

Why It Matters

Same Mechanism, Different Species

61% of US cats are overweight or obese (APOP 2022 survey). STAR-M3W runs on the same CHO-Speed™ platform as STAR-K9E with the felinized sequence swapped in, so the cost and time of reaching a second species drop sharply.

61%

US cats overweight or obese (APOP 2022)

1

Platform — shared with K9E

Mechanism of action

Fig. 1
GLP-1 receptor agonist acting on the brain, stomach and pancreas
Fig. 1. A once-weekly GLP-1 receptor agonist acts at GLP-1 receptors in the brain, stomach and pancreas to regulate appetite and glucose. Conceptual; in vivo efficacy is not yet established.

Partnering

Co-Development Partners · Territory-Exclusive Licensees

One of the two pipelines SmartGene carries to its own marketing authorisation, alongside STAR-K9E. The full package is shared under a CDA.

Request the Pipeline PackageAbout Partnering

Every programme is in development and pre-approval. Product properties, including dosing interval and efficacy endpoints, are development targets and have not been established in vivo. Technical, market and development detail is available under an executed CDA.